Last updated: February 23, 2026
What is NDC 50268-0621?
The National Drug Code (NDC) 50268-0621 refers to a specific pharmaceutical product. Based on available records, this NDC corresponds to Ubrogepant oral tablets, intended for the acute treatment of migraines.
Market Landscape
1. Indication and Market Need
Ubrogepant addresses migraine attacks, affecting approximately 12% of the U.S. population. The drug operates as a calcitonin gene-related peptide (CGRP) receptor antagonist. The migraine market is characterized by:
- An estimated 36 million Americans suffering from migraines.
- Existing treatments include triptans and gepants; the latter includes ubrogepant.
- Patients often experience suboptimal responses or contraindications with triptans.
2. Competitive Context
The competitive landscape includes:
| Product Name |
Mechanism of Action |
Market Share (2022) |
Prices (average wholesale) |
| Ubrogepant (Ubrelvy) |
CGRP antagonist |
20% |
$650-$700 per 30 tablets |
| Sumatriptan |
Triptan |
50% |
$20-$40 per 9 tablets |
| Rimegepant (Nurtec ODT) |
CGRP antagonist |
25% |
$600-$700 per 30 tablets |
Proprietary drugs like Nurtec ODT (rimegepant) present direct competition with ubrogepant. Brand loyalty and prescriber preferences influence market penetration.
3. Regulatory Status and Launch Timeline
Ubrogepant was approved by the FDA in 2019. Since then, the market has gradually expanded with increased awareness, insurer inclusion, and formulary listing.
4. Patient Access and Reimbursement
High drug prices pose access hurdles. Insurance coverage varies, influencing patient out-of-pocket costs, which ranges from $20 to over $100 per prescription, depending on insurance plans and subsidies.
Price Projections
1. Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 30 Tablets |
| 2019 |
$620 |
| 2020 |
$640 |
| 2021 |
$660 |
| 2022 |
$680 |
The prices have increased at a compound annual growth rate (CAGR) of approximately 3%. Factors influencing pricing include increased manufacturing costs, inflation, and market demand.
2. Future Price Trajectory
Forecasting based on current trends (2023-2027):
| Year |
Estimated AWP per 30 Tablets |
Assumption |
| 2023 |
$700 |
Moderate pricing increase |
| 2024 |
$720 |
Continued inflation |
| 2025 |
$740 |
Market expansion benefits |
| 2026 |
$760 |
Slight price stabilization |
| 2027 |
$780 |
Competitive price pressure |
Clinical and regulatory developments may exert downward pressures if generics enter or biosimilars emerge, but no biosimilar or generic is currently approved.
3. Price Sensitivity and Reimbursement
Prescriber and payer acceptance largely determine prices. Increasing prior authorization barriers may result in higher patient copays, which could suppress demand and limit price growth.
4. Impact of Generic Entry
Expected generic entry could reduce prices by up to 50%, anticipated 5-7 years post-approval based on typical patent exclusivity periods.
Key Market Dynamics
- Market Penetration: sales are projected to grow at ~10% annually over the next five years as awareness and insurance coverage expand.
- Pricing Power: constrained by competition and regulatory pressure; price hikes will likely be muted.
- Reimbursement Trends: insurers favor formulary placement for cost-effective options. Patient co-pay increases may temper demand.
Financial Outlook
| Metric |
2022 |
2023 |
2024 |
2025 |
2026 |
2027 |
| Estimated Market Size (USD millions) |
$1,200 |
$1,320 |
$1,454 |
$1,600 |
$1,760 |
$1,936 |
| Projected Revenue (USD millions) |
$270 |
$297 |
$327 |
$360 |
$396 |
$436 |
These projections assume a market share increasing from 20% to 30% over the forecast horizon, driven by expanding indications and increased prescriber familiarity.
Summary
Market Overview: The ubrogepant market remains competitive, with growth driven by larger unmet needs and increasing physician acceptance. Price increases are moderate and constrained by payer dynamics. The key risk remains generic entry, which could significantly reduce prices within the next 5-7 years.
Price Projections: Expected to rise gradually from approximately $700 per 30 tablets in 2023 to near $780 in 2027, barring significant market disruptions.
Key Takeaways
- NDC 50268-0621 (ubrogepant) faces competition from larger, established drugs, with a growing patient base.
- The market will see steady price growth, limited by payer pressure and eventual generic competition.
- Revenue growth depends on increased market penetration and payer management strategies.
- Price sensitivity and reimbursement policies strongly influence real-world pricing.
- Entry of generics could cut prices by approximately 50%, affecting long-term profitability.
FAQs
Q1: How does ubrogepant compare to other migraine treatments in efficacy?
Ubrogepant offers rapid relief and can be used in patients with cardiovascular risk factors, unlike triptans, which are contraindicated in such populations.
Q2: When is generic ubrogepant likely to enter the market?
Typically, generic versions appear 5-7 years after patent expiry, likely around 2024-2026.
Q3: How does insurance coverage impact the price of ubrogepant?
Coverage varies; higher copays can limit accessibility, influencing overall sales volume and revenue.
Q4: What are the main regulatory challenges for ubrogepant?
Ensuring continued safety data collection and competing for reimbursement are primary concerns post-approval.
Q5: What are the potential areas for price optimization?
Negotiating formulary inclusion, patient assistance programs, and targeted marketing can improve market share and revenue per unit.
References
[1] U.S. Food and Drug Administration. (2019). Ubrogepant approval letter.
[2] IQVIA. (2022). Pharmaceutical Market Trends.
[3] Centers for Disease Control and Prevention. (2021). Migraine prevalence and statistics.
[4] GoodRx. (2022). Migraine medication prices.
[5] Health Affairs. (2021). Drug pricing trends and impact.
